North America Diffuse Large B-cell Lymphoma Therapeutics Market Study 2022

Growing Diffuse Large B-Cell Lymphoma Therapeutics Market :

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Around 77,000 new cases of non-Hodgkin lymphoma are diagnosed in the U.S. each year and DLBCL represents approximately one in three newly diagnosed cases. The prevalence of this disease is increasing at an alarming rate, which is likely to fuel the demand for DLBCL treatments substantially shortly, leading to a considerable diffuse large B-Cell lymphoma market growth.

1. Increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma) 

Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) that affects B-lymphocytes. Although there are more than 60 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas

In the United States, DLBCL affects about 7 out of 100,000 people each year. DLBCL is a fast-growing, aggressive form of NHL. According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S. Thus, the market for diffuse large-B cell lymphoma therapeutics is expected to grow during the forecast period

DLBCL most commonly affects middle-aged and older adults. The males appear to have a predisposition to DLBCL, which is why a higher percentage of incidence was observed in males as compared to females, thus driving the market growth.

2. Increasing preference for targeted therapies 

Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer.

Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells.

Ibrutinib is a targeted therapy that inhibits Bruton's tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently

3. Increasing approvals and a robust pipeline is driving the growth of the market

North America's diffuse large b-cell lymphoma (DLBCL) therapeutics market growth is expected to be driven by increasing approvals and a robust pipeline for the development of new drugs and treatments for DLBCL. 

Some of the recent approvals for the treatment of DLBCL are highlighted below:

• On February 05, 2021, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). 
• In April 2021, ADC Therapeutics SA received the U.S. Food and Drug Administration (FDA) approval for ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma. ZYNLONTA, a CD19-targeted antibody-drug conjugate (ADC), has been granted accelerated approval by the FDA based on the overall response rate. 

The number of drugs in the development phase is increasing rapidly, as curative therapy needs to be well developed to overcome radiation therapy and other treatment options. There are more than 100 therapeutic candidates that are in the pipeline phase for DLBCL treatment, which is expected to boost the market growth over the forecast period. Alisertib (MLN8237), Brentuximab vedotin (Adcetris), Bortezomib (Velcade), Panobinostat, Everolimus (Afinitor), Lenalidomide (Revlimid), and Vorinostat (Zolinza) are some of the pipelined products.

DataM Intelligence - North America's diffuse large b-cell lymphoma therapeutics market is estimated to grow at a CAGR of 8% during the forecast period (2022-2029) to reach a market value of USD 2,445.6 million by 2028. The United States is the highest contributor to the growth of the market owing to factors such as the increasing prevalence of diffuse large b-cell lymphoma (DLBCL) cases and rising healthcare awareness among the people of this region. DLBCL, the most common type of non-Hodgkin lymphoma in the United States, is a rapidly progressing, aggressive disease that is heterogeneous with multiple subtypes. Also, increasing product approval by regulatory authorities in the region has created a lucrative market opportunity for the players in the market. The continuous development of novel treatments and drugs for treating diffuse large B-cell lymphoma via research and development in the region is assisting the growth of North America to diffuse large B-Cell lymphoma market.